The $26 billion opioid crisis MDL settlement — reached with Johnson & Johnson, McKesson, Cardinal Health, and AmerisourceBergen — stands as one of the largest civil settlements in American history, and the money is now flowing to states and local governments across the country. Finalized on February 25, 2022, after 46 states agreed to terms in July 2021, the deal requires roughly 90% of eligible local governments that opted in to direct funds toward addiction treatment, overdose prevention, and recovery services. Upward of $10 billion has already been distributed to government coffers, with payments scheduled to continue for up to 18 years depending on the defendant. But whether that money is actually reaching the people and programs that need it most is a different question entirely.
Some states, like Massachusetts, have launched public dashboards to track every dollar. Others have left millions sitting unspent while overdose deaths continue. Maine’s local governments, for instance, have spent only $3 million of their allocation so far, with $19 million still untouched and another $50 million expected over the next 12 years.
Table of Contents
- How Is the $26 Billion Opioid MDL Settlement Divided Among J&J, McKesson, Cardinal Health, and AmerisourceBergen?
- What Conduct Changes Does the Settlement Require From Drug Distributors?
- How Are States Spending Their Opioid Settlement Funds in 2026?
- Why Some Communities Have Millions Sitting Unspent — and What That Means
- Accountability Gaps and the Risk of Misused Settlement Dollars
- How Individuals and Families Affected by the Opioid Crisis Can Access Help
- What Comes Next for Opioid Settlement Accountability and Spending
- Frequently Asked Questions
How Is the $26 Billion Opioid MDL Settlement Divided Among J&J, McKesson, Cardinal Health, and AmerisourceBergen?
The three major drug distributors — McKesson, AmerisourceBergen (now operating under the name Cencora), and cardinal health — account for the bulk of the settlement at a combined $19.5 billion. McKesson is paying the most at $7.4 billion over 18 years. AmerisourceBergen follows at $6.1 billion over the same timeframe, and Cardinal Health at $6.0 billion. Johnson & Johnson, the manufacturer whose Janssen subsidiary produced opioid medications, agreed to $5 billion paid out over a shorter nine-year window. These figures represent just a portion of the broader opioid litigation landscape. When you add in settlements from CVS, Walgreens, and Walmart ($13.8 billion combined), plus the Purdue Pharma and Sackler family deal ($7.4 billion), total opioid settlements across all defendants have surpassed $54 billion.
That is a staggering number, but it is worth putting in context — the CDC has estimated the economic burden of the opioid crisis at over $1 trillion when factoring in healthcare costs, lost productivity, and criminal justice expenses. The settlements, while historic, cover a fraction of the actual damage. The extended payment timelines matter for communities trying to plan ahead. A state like Michigan, expecting roughly $800 million over 18 years, cannot simply launch every program it needs today. The money arrives in annual installments, which forces state and local officials to make difficult choices about what to fund first and what can wait. That staggered approach has been a source of frustration for public health advocates who argue that the crisis demands immediate, large-scale investment, not incremental spending stretched across nearly two decades.
What Conduct Changes Does the Settlement Require From Drug Distributors?
Beyond the dollar amounts, the settlement imposes structural reforms on the distributor defendants that may prove just as consequential as the payments themselves. McKesson, Cardinal Health, and AmerisourceBergen are required to establish a centralized independent clearinghouse designed to detect and flag suspicious opioid orders across the supply chain. This is a direct response to the pre-crisis reality in which distributors shipped enormous quantities of pills to small-town pharmacies without meaningful scrutiny, sometimes filling orders that should have raised immediate red flags. The companies must also terminate shipments to pharmacies that show signs of drug diversion — the practice of routing prescription medications to illicit use. Sales staff are now explicitly prohibited from influencing anti-diversion decisions, a provision that targets the corporate culture that previously allowed revenue targets to override safety concerns.
Senior executives must personally oversee anti-diversion efforts, creating a chain of accountability that extends to the top of each organization. However, enforcement of these provisions depends heavily on ongoing monitoring and political will. If state attorneys general do not actively hold these companies to the conduct requirements, the reforms risk becoming paper obligations. There is also a limitation worth noting — these rules apply to the settling defendants specifically. Other distributors and manufacturers not party to this settlement are not bound by the same requirements, which means gaps in supply chain oversight could persist in parts of the market these reforms do not reach.
How Are States Spending Their Opioid Settlement Funds in 2026?
State-level spending varies enormously, and several developments in early 2026 illustrate both the progress and the problems. Massachusetts launched a public dashboard to track approximately $1 billion in expected settlement funds over 18 years. The state spent $61 million in opioid recovery funds during its last fiscal year, covering treatment programs, Naloxone distribution, and recovery housing. The dashboard represents a best-case approach to transparency — residents and watchdog groups can see exactly where the money goes. Missouri released its Third Annual Report on settlement expenditures on March 2, 2026, offering another window into how one state is allocating funds.
Mississippi’s legislature unanimously passed reforms to ensure settlement dollars are directed specifically toward overdose prevention, a move prompted by concerns that some funds were being diverted to general budget items rather than addiction-related programs. That unanimous vote is notable in a politically divided legislature and suggests broad recognition that the money must serve its intended purpose. Delaware opened a new grant cycle with $3.25 million available for local governments, drawn from its total allocation of more than $200 million. On a smaller scale, Fort Wayne, Indiana used $100,000 in grant funding for community Naloxone training programs — a concrete example of how settlement dollars can translate directly into life-saving interventions at the local level. Wisconsin received $36 million in opioid settlement payments during state fiscal year 2025, adding to its growing pool of available resources.
Why Some Communities Have Millions Sitting Unspent — and What That Means
The gap between receiving settlement funds and actually deploying them is one of the most pressing issues in the opioid settlement story. Maine offers a stark illustration. Local governments there have spent just $3 million of their opioid settlement funds so far, while $19 million sits unspent. Another $50 million is expected to arrive over the next 12 years. The reasons for the delay are not always negligence — smaller municipalities often lack the administrative infrastructure to design programs, hire staff, issue grants, and track outcomes. There is a real tradeoff at play here.
Spending quickly means getting resources to people who need them now, but it also increases the risk of waste, fraud, or funding programs that do not actually reduce overdose deaths. Spending slowly allows for more careful planning but means people die in the interim waiting for treatment beds, harm reduction supplies, and recovery services that the money was meant to provide. States that have invested in dedicated opioid settlement commissions or advisory boards tend to deploy funds more effectively than those that have simply folded the money into existing bureaucratic channels. The comparison between Massachusetts and Maine is instructive. Massachusetts has spent $61 million and built a public tracking dashboard. Maine’s local governments have spent $3 million total. Both states are dealing with serious opioid crises, but the difference in institutional capacity and political prioritization has led to vastly different outcomes in how settlement funds reach communities.
Accountability Gaps and the Risk of Misused Settlement Dollars
History offers a cautionary tale. The 1998 tobacco Master Settlement Agreement sent over $200 billion to states, and much of that money was redirected to general budgets, road construction, and other purposes with no connection to public health. Opioid settlement advocates have fought hard to prevent a repeat, but the risk is real. Mississippi’s 2026 legislative reforms were driven by exactly this concern — a recognition that without statutory guardrails, settlement dollars can quietly drift away from their intended purpose. Not every state has adopted the same level of oversight. Some states have created independent commissions to oversee opioid settlement spending.
Others have given broad discretion to governors or legislatures, which can result in funds being used to fill budget shortfalls rather than expand treatment capacity. The National Academy for State Health Policy tracks state-by-state opioid settlement spending decisions, and the variation is significant. Communities that want to ensure their local allocation is being used appropriately should check whether their state publishes spending reports and whether an independent body reviews how funds are deployed. A further limitation is that settlement funds, no matter how large, cannot fully replace sustained public health investment. The $26 billion spread across 46 states over 18 years amounts to meaningful but limited resources relative to the scale of the crisis. States that treat settlement dollars as a supplement to existing funding — rather than a replacement for it — are better positioned to make a lasting impact.
How Individuals and Families Affected by the Opioid Crisis Can Access Help
Unlike many class action settlements, the opioid MDL settlement does not provide direct payments to individuals. The money flows to state and local governments, which then decide how to allocate it across treatment programs, Naloxone distribution, recovery support services, and prevention efforts. This means that individuals and families affected by the crisis need to look to their local and state programs for assistance rather than filing individual claims under this particular settlement.
That said, some of the funded programs do serve individuals directly. Fort Wayne, Indiana’s $100,000 Naloxone training program is one example — residents can attend community sessions to learn how to administer the overdose-reversing medication. Delaware’s $3.25 million grant cycle for local governments may fund treatment slots, peer recovery coaches, or syringe service programs that individuals can access. The best starting point is contacting your state’s opioid settlement commission or your local health department to find out what programs are available in your area.
What Comes Next for Opioid Settlement Accountability and Spending
The opioid settlement is still in its relatively early stages. With payments from McKesson, AmerisourceBergen, and Cardinal Health stretching through 2039 and beyond, the question of how effectively these funds are used will unfold over more than a decade. The trend toward greater transparency is encouraging — Massachusetts’ dashboard, Missouri’s annual reports, and Mississippi’s legislative reforms all suggest that public pressure is pushing states toward accountability.
Looking ahead, the centralized clearinghouse required of the distributor defendants will be a critical test of whether the conduct reforms have teeth. If the clearinghouse functions as intended, it should flag and prevent the kind of mass over-distribution that fueled the crisis. But sustained vigilance from state attorneys general, public health officials, and the public will be necessary to ensure that both the money and the reforms deliver on their promise. More than $54 billion in total opioid settlements means nothing if the funds are not translated into treatment beds, harm reduction supplies, and genuine support for the communities that have been devastated by this epidemic.
Frequently Asked Questions
How much is the total opioid MDL settlement with J&J, McKesson, Cardinal Health, and AmerisourceBergen?
The settlement totals $26 billion, finalized on February 25, 2022. McKesson pays $7.4 billion, AmerisourceBergen (Cencora) pays $6.1 billion, Cardinal Health pays $6.0 billion, and Johnson & Johnson pays $5 billion. Payments are spread over 9 to 18 years depending on the defendant.
Can individuals file claims for direct payments from the opioid settlement?
No. This settlement pays state and local governments, not individuals. The funds are meant to be used for addiction treatment, overdose prevention, recovery services, and related public health programs. Individuals should contact their state opioid settlement commission or local health department to learn about funded programs they can access.
How much total money has been committed across all opioid settlements?
Over $54 billion in total opioid settlements have been reached across all defendants, including the $26 billion from this MDL settlement, $13.8 billion from CVS, Walgreens, and Walmart, and $7.4 billion from Purdue Pharma and the Sackler family. Upward of $10 billion has been distributed to government coffers so far.
How can I find out how my state is spending opioid settlement funds?
Several states now publish spending reports or dashboards. Massachusetts launched a public dashboard to track its approximately $1 billion allocation. Missouri publishes annual reports on settlement expenditures. The National Academy for State Health Policy and KFF Health News both maintain trackers that allow you to look up opioid settlement spending by state and locality.
What reforms are required of the drug distributors under the settlement?
The three distributors must establish a centralized independent clearinghouse to detect suspicious opioid orders, terminate shipments to pharmacies showing signs of diversion, prohibit sales staff from influencing anti-diversion decisions, and require senior executives to personally oversee anti-diversion compliance efforts.
Is there a risk that opioid settlement money will be misspent?
Yes. The 1998 tobacco settlement saw billions redirected to non-health purposes, and similar concerns exist here. Some states have created independent oversight commissions and passed legislation requiring funds be used for opioid-related purposes. Mississippi passed unanimous reforms in March 2026 specifically to prevent diversion of settlement dollars away from overdose prevention.